Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Cystic Fibrosis
In brief
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single dose of VX-581 and multiple ascending doses of VX-581 alone and in combination with tezacaftor (TEZ)/deutivacaftor (D-IVA) or D-IVA for up to ten days.
Key facts
- Study ID
- NCT07283770
- Run by
- Vertex Pharmaceuticals Incorporated
- People needed
- 136
- Starts
- 2025-12-09
- Expected to finish
- 2026-11-19
- Last updated by the study team
- 2026-07-16
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Altasciences - Kansas City — Overland Park, Kansas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.